AR087470A1 - Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen - Google Patents

Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen

Info

Publication number
AR087470A1
AR087470A1 ARP120102871A ARP120102871A AR087470A1 AR 087470 A1 AR087470 A1 AR 087470A1 AR P120102871 A ARP120102871 A AR P120102871A AR P120102871 A ARP120102871 A AR P120102871A AR 087470 A1 AR087470 A1 AR 087470A1
Authority
AR
Argentina
Prior art keywords
independently
bifenilenic
pharmaceutical compositions
compositions containing
salts
Prior art date
Application number
ARP120102871A
Other languages
English (en)
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of AR087470A1 publication Critical patent/AR087470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Sales de los compuestos, una composición farmacéutica que comprende los compuestos o sales, y útiles para el tratamiento de la infección por el virus de hepatitis C (HCV) mediante la administración de los compuestos o sales.Reivindicación 1: Un compuesto de la fórmula (1) en donde cada R es independientemente -CH(R1)-NH-C(O)-OR2; en donde cada R1 es independientemente -CH(OH)-CH3 o -CH(OCH3)-CH3; y cada R2 es independientemente alquilo de 1 a 3 átomos de carbono. Reivindicación 14: Un compuesto de la fórmula (2) o de la fórmula (3): en donde X1 y X2 son independientemente O, SO2, NCH3, CF2, CH2, CH2CH2, o un enlace (es decir, están ausentes); y cada R es independientemente -CH(R1)-NH-C(O)-OR2; en donde cada R1 es independientemente -CH(OH)-CH3 o -CH(OCH3)-CH3; y cada R2 es independientemente alquilo de 1 a 3 átomos de carbono.
ARP120102871A 2011-08-08 2012-08-06 Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen AR087470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515990P 2011-08-08 2011-08-08

Publications (1)

Publication Number Publication Date
AR087470A1 true AR087470A1 (es) 2014-03-26

Family

ID=47668848

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102871A AR087470A1 (es) 2011-08-08 2012-08-06 Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen

Country Status (6)

Country Link
US (1) US8889726B2 (es)
EP (1) EP2741746A4 (es)
AR (1) AR087470A1 (es)
TW (1) TW201321373A (es)
UY (1) UY34245A (es)
WO (1) WO2013022810A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303061B2 (en) 2011-07-09 2016-04-05 Sunshine Luke Pharma Co., Ltd. Spiro compounds as Hepatitis C virus inhibitors
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR101919194B1 (ko) * 2015-09-15 2018-11-15 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
EP2410843A4 (en) 2009-03-27 2012-08-08 Presidio Pharmaceuticals Inc FUSIONED CORE INHIBITORS OF HEPATITIS C
CA2760205A1 (en) * 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
JP2013518062A (ja) 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物

Also Published As

Publication number Publication date
WO2013022810A1 (en) 2013-02-14
US20140171476A1 (en) 2014-06-19
EP2741746A1 (en) 2014-06-18
TW201321373A (zh) 2013-06-01
US8889726B2 (en) 2014-11-18
EP2741746A4 (en) 2014-12-31
UY34245A (es) 2013-02-28

Similar Documents

Publication Publication Date Title
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
UY32490A (es) Inhibidores de beta-secretasa
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
CR20190504A (es) COMPUESTO DE AMIDA (Divisional 2015-0454)
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR063165A1 (es) Derivados de acido boronico como inhibidores de amidihidrolasa de acidos grasos. composiciones farmaceuticas.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
DOP2014000121A (es) Derivados de betulina
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR085327A1 (es) Inhibidores del virus de la hepatitis c
NZ739248A (en) Inhibitors of hepatitis c virus
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.

Legal Events

Date Code Title Description
FB Suspension of granting procedure